The first Amgen Golden Ticket To BioLabs LA will be presented to AmGen and The Lundquist Institute - The First Amg And The Second Time In America!
Amgen announced today that the first Golden Ticket of the AmGen Golden-Ticket in Southern California was issued in the State of California, Sept. 14, 2021. Diadem will receive an annual lab space at BioLabs LA at The Lundquist Institute (TLI), and additional facility benefits and connections to Amgen's scientific and business leaders.
The 2021 Amgen Golden Ticket winner was selected by an intern team of AmGen scientific leaders at a virtual pitch event. This is the first of three Golden Tickets awarded over the next three years to help accelerate life science start-ups in Southern California. Five finalists pitched their business plans before the Amgen internal committee that evaluated the strength and novelty of their scientific
The announcement is a matter of mind.
- The partnership with BioLabs LA at The Lundquist Institute recognizes the rapid growth of bioscience innovation in Los Angeles and aligns with our desire to bring breakthrough therapies for patients. Philip Tagari, Ph.D., vice president of Therapeutic Discovery at Amgen, is enthusiastic about the exosome technology that is being developed by Diadem Biosciences and is eager to work with the team as they advance novel immuno
- "Biolabs LA at the Lundquist Institute honors its collaboration with Amgen, a global pioneer in biotechnology, to help identify and support innovative life-science companies in Southern California. The three-year Golden Ticket sponsorship of Amgen provides a unique opportunity for BioLabs to help stimulate the startup industry in the rapidly evolving Los Angeles market and improve the performance of their startup companies. Amgen is a model and guidepost to encourage and champion companies to grow with local resources being crucial to their success. We hope that Diadem joins the BioLabs LA community and will help them, along with Amgen and The Lundquist Institute, reach their milestones. Lindsay Bourgeois, director of BioLabs LA at the Lundquist Institute. "We're working together to advance the field of human biology and patient health." - Lindsay, Bourgesoi,
- "We are pleased to have an expert judging panel of Amgen's leading scientists endorsed our approach to therapeutic signaling." With the extensive resources at BioLabs LA and access to Amgen expertise, we can accelerate the development of a new class of therapeutics that could improve patient-care outcomes across varying diseases. Mickey Pentecost, Ph.D., co-founder and chief executive officer of Diadem Biotherapeutics Inc.
Amgen supports life science start-ups through Golden Ticket awards and affiliated engagement in other biotech innovative hubs, including San Francisco, Boston and Toronto.
About Diadem Biotherapeutics Inc. Diadem Biotherapeutics Inc. A platform therapeutics company develops a broad pipeline of first-class immunotherapies. Diadem is developing cell-based nanovesicles that are precisely engineered to deliver signals that mimic natural cell communication. Diam is utilizing expertise in genetic engineering and scalable bioprocessing to develop cell secreted nano- Diadem's unique approach enables precise modulation of targets that play a key role in chronic inflammation, autoimmune diseases and immune control of cancers, and addressing critical unmet clinical needs.
Amgen about Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach starts by using advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen is focused on areas of high unmet medical needs and uses its expertise to seek solutions that improve the health and life of people. Amgen has grown to become one of the world's leading independent biotechnology companies, has reached millions of patients around the globe and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.
The Lundquist Institute: Research with reachTM. The Lundquist Institute is a pioneer of innovation with global reach and 69-year reputation of improving and saving lives. The Lundquist Institute is a hub for the Los Angeles area's rapidly changing biotech scene. With its new medical research building, its state-of-the-art incubator, "BioLabs at The Laund There are over 100 principal investigators (Ph.D.s, M.S. and MD/PhedD) working on more than 600 research studies, including therapies for numerous and often fatal orphan diseases. Find out more at https://lundquist.org.
About BioLabs LA at The Lundquist Institute About The Laundqusa Institute. BioLabs LA is the new medical research lab building built on the third floor of the Lundquist Institute's new Medical Research Laboratory Building. The facility allows companies to experience high-potential, early-stage life. BioLabs creates co-working communities that combines premium, fully equipped and supported lab and office space with unparalleled access to networking, industry partners and capital.
AmgenMichael Strapazon, 805-313-5553 (media) 835-333-5553 (metro) (advance)
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterKeith B. Hoffman, Ph.D., (310) 974-9301, [email protected]
BioLabs LALindsay Bourgeois, (978) 852-1081, [email protected] (Alindon, cl.
SOURCE Amgen SURCE-AMGEN SHERCE AMGEN.